Tyrosine ( DrugBank: Tyrosine )
3 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 6 | Parkinson disease | 3 |
| 86 | Pulmonary arterial hypertension | 6 |
| 111 | Congenital myopathy | 1 |
6. Parkinson disease
Clinical trials : 2,298 / Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03655236 (ClinicalTrials.gov) | February 18, 2019 | 18/8/2018 | PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects With Early Parkinson's Disease | Early Parkinson Disease | Drug: K0706;Other: placebo | Sun Pharma Advanced Research Company Limited | NULL | Recruiting | 50 Years | N/A | All | 504 | Phase 2 | United States;Hungary;India;Poland;Slovakia;Spain |
| 2 | NCT02259049 (ClinicalTrials.gov) | October 2014 | 3/10/2014 | The Effects of L-Tyrosine on 24 Hour Blood Pressure and Heart Rate in Parkinson's Disease | The Effects of L-Tyrosine on Non-invasive Ambulatory Blood Pressure and Heart Rate Monitoring in Parkinson's Disease | Blood Pressure | Dietary Supplement: L-tyrosine;Dietary Supplement: Sugar Pill | New York Institute of Technology | NULL | Completed | 40 Years | 84 Years | Both | 6 | Phase 0 | United States |
| 3 | NCT01676103 (ClinicalTrials.gov) | September 2012 | 28/8/2012 | The Effects of Supplementing Tyrosine on Blood Pressure in Parkinson's Disease | The Effects of Supplementing Tyrosine on Blood Pressure in Parkinson's Disease | Parkinson's Disease | Dietary Supplement: Tyrosine;Other: Placebo Comparator:Sugar Pill | New York Institute of Technology | Michael J. Fox Foundation for Parkinson's Research | Completed | 50 Years | 80 Years | Both | 40 | Phase 1/Phase 2 | United States |
86. Pulmonary arterial hypertension
Clinical trials : 1,181 / Drugs : 701 - (DrugBank : 126) / Drug target genes : 105 - Drug target pathways : 192
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-UMIN000001709 | 2009/02/01 | 16/02/2009 | Multikinase Inhibitor (Tyrosine and Serine/Threonine Kinase Inhibitor) for the Treatment of Severe Pulmonary Arterial Hypertension | pulmonary arterial hypertension | administration of sorafenib, which is the multikinase inhibitor (tyrosine and serine/threonine kinase inhibitor) | Medical Education Center, School of Medicine, Keio University | NULL | Pending | 20years-old | Not applicable | Male and Female | 10 | Not selected | Japan | |
| 2 | JPRN-UMIN000001578 | 2008/12/01 | 16/12/2008 | Tyrosine Kinase Inhibitor for the Treatment of Severe Pulmonary Arterial Hypertension | pulmonary arterial hypertension | administration of tyrosine kinase inhibitor (imatinib) | Medical Education Center | NULL | 20years-old | Not applicable | Male and Female | 10 | Not selected | Japan | ||
| 3 | EUCTR2005-005569-12-AT (EUCTR) | 11/08/2006 | 13/07/2006 | A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of six months treatment with the tyrosine kinase inhibitor of STI571 for the treatment of pulmonary arterial hypertension. | A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of six months treatment with the tyrosine kinase inhibitor of STI571 for the treatment of pulmonary arterial hypertension. | pulmonary arterial hypertension | Product Name: Glivec Product Code: STI571 INN or Proposed INN: Imatinib | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | Austria;Germany;United Kingdom | ||||
| 4 | EUCTR2005-005569-12-DE (EUCTR) | 24/05/2006 | 27/03/2006 | A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of six months treatment with the tyrosine kinase inhibitor of STI571 for the treatment of pulmonary arterial hypertension. | A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of six months treatment with the tyrosine kinase inhibitor of STI571 for the treatment of pulmonary arterial hypertension. | pulmonary arterial hypertension | Trade Name: Glivec 100 mg Hartkapsel Product Name: Glivec Product Code: STI571 INN or Proposed INN: Imatinib Trade Name: Glivec 100 mg Filmtabletten Product Name: Glivec Product Code: STI571 INN or Proposed INN: Imatinib | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 60 | Austria;Germany;United Kingdom | |||
| 5 | NCT00477269 (ClinicalTrials.gov) | April 2006 | 22/5/2007 | Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension | A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of the Six Months Treatment With the Tyrosine Kinase Inhibitor STI571 for the Treatment of Pulmonary Arterial Hypertension (PAH) | Pulmonary Arterial Hypertension | Drug: Imatinib mesylate;Drug: Placebo | Novartis Pharmaceuticals | NULL | Completed | 18 Years | N/A | All | 59 | Phase 2/Phase 3 | United States;Austria;Germany;United Kingdom |
| 6 | EUCTR2005-005569-12-GB (EUCTR) | 26/01/2006 | 02/12/2005 | A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of six months treatment with the tyrosine kinase inhibitor of STI571 for the treatment of pulmonary arterial hypertension. | A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of six months treatment with the tyrosine kinase inhibitor of STI571 for the treatment of pulmonary arterial hypertension. | pulmonary arterial hypertension | Trade Name: Glivec Product Name: Glivec Product Code: STI571 INN or Proposed INN: Imatinib Product Code: STI571 INN or Proposed INN: Imatinib | Novartis Pharma Services AG | NULL | Not Recruiting | Female: yes Male: yes | 60 | Austria;Germany;United Kingdom |
111. Congenital myopathy
Clinical trials : 11 / Drugs : 17 - (DrugBank : 5) / Drug target gene : 1 - Drug target pathways : 9
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02035501 (ClinicalTrials.gov) | January 2014 | 2/7/2013 | Treatment of TNNT1-Myopathy With L-Tyrosine. | Treatment of TNNT1-Myopathy With L-Tyrosine. A Double-blind, Placebo-controlled Crossover Trial. | Nemaline Myopathy | Drug: L-Tyrosine;Drug: Placebo | Hadassah Medical Organization | NULL | Enrolling by invitation | N/A | 20 Years | Both | 10 | Phase 2 | Israel |